SPIRITT Scintigraphy for Prediction In Rheumatoid Intentional Therapy Tapering

Start date: 5 March 2025
End date: 1 September 2026
Value: £100,000
Partners and collaborators: Guy’s and St Thomas’ NHS Foundation Trust of Guy’s Hospital, King's College London, Leeds Teaching Hospitals NHS Trust
Primary investigator: Professor Andrew Cope
Co-investigators: Dr Kulveer Mankia
Postgraduate students: Dr Helen Sugden

Description

Funder: Versus Arthritis

The purpose of this study is to determine whether baseline 99mTc-maraciclatide is predictive of risk of flare in RA patients tapering biologic therapy who are in in low disease activity or remission